Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/9501
Title: C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension
Authors: Quarck, R.
NAWROT, Tim 
Meyns, Bart
Delcroix, M.
Issue Date: 2009
Publisher: ACC Publications
Source: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 53(14). p. 1211-1218
Abstract: OBJECTIVES: Our aim was to investigate in a prospective study a potential role of C-reactive protein (CRP) in predicting the outcome in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). BACKGROUND: CRP is a well-known marker of inflammation and tissue damage, widely recognized as a risk predictor of cardiovascular and coronary heart diseases. METHODS: Plasma levels of CRP have been measured in consecutive patients diagnosed with PAH and CTEPH, at the time of right heart catheterization. RESULTS: Circulating CRP levels were increased in CTEPH and PAH patients compared with those in control subjects (4.9 mg l(-1), 95% confidence interval [CI]: 3.9 to 6.2 mg l(-1); 4.4 mg l(-1), 95% CI: 3.5 to 5.4 mg l(-1); and 2.3 mg l(-1), 95% CI: 1.9 to 2.7 mg l(-1), respectively; p < 0.0001). In PAH patients, CRP levels correlated with New York Heart Association functional class (r = 0.23), right atrial pressure (r = 0.25), and 6-min walking distance (r = -0.19) and were significantly higher in nonsurvivors than in survivors (p = 0.003). All PAH, idiopathic PAH, and patients naive for disease-specific medication with CRP levels >5.0 mg l(-1) had a significantly lower survival rate (p = 0.02, p = 0.009, and p < 0.05, respectively). In CTEPH patients, circulating CRP levels significantly decreased 12 months after pulmonary endarterectomy (n = 23, 4.0 mg l(-1), 95% CI: 2.8 to 5.8 mg l(-1), to 1.6 mg l(-1), 95% CI: 2.2 to 3.0 mg l(-1); p = 0.004). PAH patients normalizing their CRP levels under treatment (n = 29), assigned as responders, had a significantly higher survival rate (p < 0.05). The proportion of patients treated with a parenteral prostacyclin-analogue was significantly higher among the responders than the nonresponders (55% vs. 17%, p = 0.002). CONCLUSIONS: This is the first evidence of a role of an inflammatory marker, such as CRP, in predicting outcome and response to therapy in PAH.
Keywords: inflammation, pulmonary arterial hypertension, prospective cohort study
Document URI: http://hdl.handle.net/1942/9501
ISSN: 0735-1097
e-ISSN: 1558-3597
DOI: 10.1016/j.jacc.2008.12.038
ISI #: 000264724500008
Category: A1
Type: Journal Contribution
Validations: ecoom 2010
Appears in Collections:Research publications

Show full item record

SCOPUSTM   
Citations

169
checked on Sep 3, 2020

WEB OF SCIENCETM
Citations

199
checked on Jul 10, 2024

Page view(s)

44
checked on Jul 31, 2023

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.